Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO5: Treatment Strategies in Colorectal Cancer with Unresectable Liver Metastases
NCT02162563Phase 3Completed
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Jul 2014
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Nanoparticles, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of panitumumab, fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in colorectal cancer (CRC), sponsored by Dutch Colorectal Cancer Group. Started Jul 2014; status: completed.
02
Drugs
panitumumabfluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02162563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162563.